ArticleOncotarget2017
Antitumor activity of gemcitabine against high-grade meningioma
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.International journal of molecular sciences · 2026Article
- Sensitising PDAC to Gemcitabine by Suppressing NF-κB Pathway and Enhancing Apoptosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Development and validation of a prognostic nomogram for overall survival in individuals with malignant meningiomas: a population-based study.Scientific reports · 2025Article
- Beyond Nucleotide Excision Repair: The Importance of XPF in Base Excision Repair and Its Impact on Cancer, Inflammation, and Aging.International journal of molecular sciences · 2024Review
- Emerging systemic treatment options in meningioma.Journal of neuro-oncology · 2023Review
- Preclinical Models of Meningioma.Advances in experimental medicine and biology · 2023Review
- Article
- Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.Cancer science · 2022Article
- Will mastering ferroptosis allow treating refractory meningiomas?Neuro-oncology · 2021Article
- Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.Neuro-oncology · 2021Article
- Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.Biomolecules · 2021Article
- Gemcitabine in Recurrent Meningioma.South Asian journal of cancer · 2020Article
- Article
- Molecular and translational advances in meningiomas.Neuro-oncology · 2019Review
- Caspase 3 Expression Profiles in Meningioma Subtypes Based on Tissue Microarray Analysis.Cancer diagnosis & prognosisArticle
- Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is no established therapeutic option for high-grade meningioma recurring after surgery and radiotherapy, and few chemotherapeutic agents are in development for the treatment of high-grade meningioma. Here in this study, we screened a panel of chemotherapeutic agents for their possible antitumor activity in high-grade meningioma and discovered that high-grade meningioma cells show a preferential sensitivity to antimetabolites, in particular, to gemcitabine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.